Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

  Authors:S.P. Graham et al. 

Journal/ Pre-Print:bioRxiv 

Key Words:vaccination, ChAdOx1 nCoV-19 

Research Highlights 

  1. A booster immunisation 28 days post prime vaccination slightly increases spike-peptide reactive CD4 and CD8 T cell numbers in pigs, but not in mice. 

  1. The booster immunisation enhanced binding antibody titers in BALB/c mice and pigs, with a concomitant significant increase in SARS-CoV-2 neutralising titres in pigs.  

Summary

Immunogenicity of a single administration of the adenoviral vector expressing SARS-CoV-2 spike protein (ChAdOx1 nCoV-19) was demonstrated previously in macaques. Here, the effect of a booster administered 28 days post initial immunisation is determined in mice and pigs. The booster immunisation slightly increases spike-peptide reactive CD4 and CD8 T cell numbers in pigs, but not in mice. It did enhance the antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres. 

Impact for SARS-CoV2/COVID19 research efforts  

Develop a vaccine for SARS-CoV2/COVID19 

Study Type  

  • In vitro study 

  • In vivo study; BALB/c and CD1 mice, and pigs 

Strengths and limitations of the paper 

Novelty: A prime-boost strategy is more effective than a single dose of ChAdOx1 nCoV-19 

Standing in the field:An increase in immune response is expected upon booster. Interestingly, the Moderna vaccine prime+booster has superior antibody titers, whereas ChAdOx1 nCoV-19 has superior cellular responses.  

Appropriate statistics: Appropriate; ANOVA or a mixed-effects model were conducted to 

compare responses over time and between vaccine groups at different time points post-vaccination. 

Viral model used:Lentiviral-based SARS-CoV-2 pseudoviruses for neutralisation responses 

SARS-CoV-2 isolate England-2 stocks also used for neutralisation responses 

Translatability:ChAdOx1 nCoV-1 is in phase I clinical trials and already cGMP produced by AstraZeneca. 

Main limitations: Authors have not demonstrated protection after prime and booster vaccine to a challenge of the pigs (not sure if possible) or at least the mice (with mouse-adapted SARS-CoV-2)  

Low number of pigs. 

No clear marking of significance in the figures. 

Limited data.